ArticleThe pharmacogenomics journal2008
Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment.
Article in The pharmacogenomics journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Model-based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review.Addiction (Abingdon, England) · 2017Pooled it
- Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models.PharmacoEconomics · 2012Pooled it
- Cost effectiveness of pharmacogenomics: a critical and systematic review.PharmacoEconomics · 2010Pooled it
- A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations.Frontiers in genetics · 2023Article
- Comprehensive Parent-Metabolite PBPK/PD Modeling Insights into Nicotine Replacement Therapy Strategies.Clinical pharmacokinetics · 2020Article
- The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions.Cancer prevention research (Philadelphia, Pa.) · 2020Review
- Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration.American journal of respiratory and critical care medicine · 2018Review
- Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016Review
- Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions.The pharmacogenomics journal · 2016Article
- Biomarkers to optimize the treatment of nicotine dependence.Biomarkers in medicine · 2011Review
- Breaking barriers in the genomics and pharmacogenetics of drug addiction.Clinical pharmacology and therapeutics · 2010Review
- Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment.Addiction science & clinical practice · 2010Review
- Nicotinic acetylcholine receptor genes on chromosome 15q25.1 are associated with nicotine and opioid dependence severity.Human genetics · 2010Article
- Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?Cost effectiveness and resource allocation : C/E · 2010Article
- Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities.Pharmacogenomics · 2010Review
- Smoking cessation: an economic analysis and review of varenicline.ClinicoEconomics and outcomes research : CEOR · 2009Article
- Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.Journal of neurogenetics · 2009Review
- Personalized medicine and tobacco-related health disparities: is there a role for genetics?Annals of family medicineArticle
- Chronic disease, medications and lifestyle: perceptions from a regional Victorian Aboriginal community.Pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
We evaluated the cost-effectiveness of a range of smoking cessation drug treatments, including varenicline, transdermal nicotine (TN), bupropion and the use of a genetic test to choose between TN and bupropion. We performed Monte Carlo simulation with sensitivity analysis, informing analyses with published estimates of model parameters and current prices for genetic testing and smoking-cessation therapy. The primary outcomes were discounted life-years (LY) and lifetime tobacco-cessation treatment costs. In the base case, varenicline treatment was optimal with an ICER, compared to bupropion, of $2985/LY saved. In sensitivity analyses, varenicline was in all cases (and bupropion in most cases) admissible; only under favorable assumptions was the genetically tailored approach competitive. Our data suggest that an untailored approach of treatment with either bupropion or varenicline is a cost-effective form of tobacco dependence treatment, but a tailored approach for selecting between TN and bupropion can be cost-effective under plausible assumptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.